{"database": "lobbying", "table": "lobbying_activities", "rows": [[3244231, "2135d0ea-37ea-4b65-9a02-0feb6c2dd812", "Q3", "FORBES-TATE", 400976792, "AMGEN USA, INC.", 2024, "third_quarter", "MED", "Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2024-10-17T14:39:04-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3244231"], "units": {}, "query_ms": 0.27860002592206, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}